New oral diabetes drugs may also protect patients' kidney health

August 18, 2016, American Society of Nephrology

A recent study indicates that a new class of oral diabetes drugs may help protect patients' kidney health in addition to lowering their blood sugar levels. The findings appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

Agents that inhibit the sodium-glucose cotransporter 2 (SGLT2) in the kidney lower by augmenting excretion of glucose in the urine. In addition, this new class of anti-diabetes medication lowers blood pressure and body weight. The effects of SGLT2 inhibitors on have not been thoroughly assessed, however.

To investigate, a team led by Hiddo Lambers Heerspink, PhD (University Medical Center Groningen, in the Netherlands) analyzed 2 years of data from a comparing the SGLT2 inhibitor canagliflozin and another diabetes drug called . (Glimepiride is a sulfonylurea, which increases insulin release from cells in the pancreas.) The analysis included 1450 patients with type 2 diabetes receiving metformin who were randomly assigned to either once-daily canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride uptitrated to 6 to 8 mg. Estimated (eGFR) was measured to assess kidney function.

Glimepiride, canagliflozin 100 mg, and canagliflozin 300 mg groups had eGFR declines of 3.3, 0.5, and 0.9 ml/min per 1.73 m2 per year, respectively. Patients receiving glimepiride, canagliflozin 100 mg, or canagliflozin 300 mg had reductions in HbA1c (a measure of blood sugar) of 0.81%, 0.82%, and 0.93%, respectively, at 1 year and 0.55%, 0.65%, and 0.74%, respectively, at 2 years.

The findings indicate that canagliflozin slows the progression of kidney function decline to a greater extent than glimepiride, while having similar blood sugar-lowering effects.

"Since glycemic control was only modestly different between canagliflozin and glimepiride, our results suggest that potential kidney protective effects of canagliflozin may be unrelated to glycemic control," said Dr. Heerspink. "Our results are especially important since many patients with diabetes are at risk of progressive kidney function loss and canagliflozin may offer a new and improved therapeutic opportunity for these patients."

In an accompanying editorial, Ian de Boer, MD and Steven Kahn, MB, ChB (University of Washington and VA Puget Sound Health Care System) noted that the kidney-protective effects of SGLT2 inhibitors add to exciting results suggesting that this class of medications may also reduce cardiovascular events such as heart attacks and strokes. "The apparent renal and cardiovascular benefits of SGLT2 inhibitors will encourage primary care physicians and endocrinologists to use these agents more frequently in the care of patients with type 2 diabetes," they wrote. "Of course, adverse effects, costs, alternative agents, and individual patient characteristics must also be taken into account."

Explore further: Effectiveness of canagliflozin in treating type 2 diabetes

More information: "Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects," August 18, 2016, DOI: 10.1681/ASN.2016030278.

Editorial "SGLT2 Inhibitors—Sweet Success for Diabetic Kidney Disease?" August 18, 2016, DOI: 10.1681/ASN. 2016060650.

Related Stories

Effectiveness of canagliflozin in treating type 2 diabetes

July 6, 2016
Research led by the University of Dundee has found that one of a new breed of drugs, which have been approved for treatment of type 2 diabetes, may be particularly effective without the need to be used in combination with ...

Type 2 diabetes mellitus: Added benefit of canagliflozin is not proven

June 17, 2014
Canagliflozin (trade name: Invokana) has been approved since November 2013 as monotherapy and in various combination therapies for adults with type 2 diabetes mellitus when diet and exercise alone do not provide adequate ...

Low incidence of diabetic ketoacidosis with canagliflozin

July 29, 2015
(HealthDay)—For canagliflozin-treated patients with type 2 diabetes, the incidence of serious adverse events of diabetic ketoacidosis (DKA) is low, according to research published online July 22 in Diabetes Care.

FDA issues warning for type 2 diabetes drugs

May 18, 2015
(HealthDay)—A certain class of type 2 diabetes drugs can lead to a life-threatening condition called ketoacidosis, the U.S. Food and Drug Administration warns.

Type 2 diabetes: Added benefit of canagliflozin plus metformin is not proven

November 21, 2014
The fixed combination of canagliflozin with metformin (trade name: Vokanamet) has been approved since April 2014 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control. ...

FDA staff: J&J diabetes drug may pose heart risk

January 8, 2013
Federal drug reviewers think Johnson & Johnson's experimental diabetes drug might bring heart risks because it raised cholesterol levels in patient testing.

Recommended for you

Scientists identify potential drug target in blood-feeding hookworms

March 22, 2018
In hookworms that infect and feed on the blood of mice, scientists have discovered a key step in blood digestion that can be targeted to disrupt the parasite's development and survival. These findings, published in PLOS Pathogens ...

Global burden of low back pain—a consequence of negligence and misinformation

March 21, 2018
A series of groundbreaking papers from Australian and international researchers in The Lancet, published today (22/3) warns that low back pain is a major health burden globally - across developed and developing nations - ...

Microscopic 'shuttles' transport enzyme from cells to trigger onset of kidney disease

March 21, 2018
A new study involving the University of Sheffield has identified a key culprit in the onset of kidney disease in a major marker for kidney disease development.

Metabolite therapy proves effective in treating C. difficile in mice

March 20, 2018
A team of UCLA researchers found that a metabolite therapy was effective in mice for treating a serious infection of the colon known as Clostridium difficile infection, or C. difficile.

Study of COPD patients has created a 'looking glass' into genome of pathogen

March 19, 2018
Decades of work on chronic obstructive pulmonary disease (COPD) at the University at Buffalo and the Veterans Affairs Western New York Healthcare System have yielded extraordinary information about the pathogen that does ...

Sick air travelers mostly likely to infect next row: study

March 19, 2018
People who fly on airplanes while contagious can indeed get other people sick, but the risk is mainly to those seated next to them or in the adjacent row, US researchers said Monday.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.